Myriad Genetics, Inc.
Financials
Valuation Metrics
Myriad Genetics, Inc.'s Market Cap is $285M. At end of 2025 it was $574M. Ranked #2967 of 3,111 in US market (top 95%), #1335 of 1,445 on NASDAQ (top 92%), #188 of 206 in Health Care Equipment & Services (top 91%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $285M | US#2,967/3,111 Sec#188/206 |
| Revenue | $829M | US#2,053/3,111 Sec#125/206 |
| Net Income | $-400M | US—/3,111 Sec—/206 |
| Total Assets | $674M | US#2,632/3,111 Sec#148/206 |
| Net Assets | $337M | US#2,497/3,111 Sec#144/206 |
| Employees | 2,700 | US#1,037/3,111 Sec#86/206 |
| Value | ||
| P/B | 0.85x | US#220/3,111 Sec#12/206 |
| P/S | 0.34x | US#162/3,111 Sec#17/206 |
| FCF Yield | -8.13% | US—/3,111 Sec—/206 |
| Profitability | ||
| ROE | -118.52% | US#2,874/3,111 Sec#187/206 |
| ROA | -59.36% | US#3,008/3,111 Sec#203/206 |
| Op. Margin | -46.26% | US#2,773/3,111 Sec#185/206 |
| Revenue Growth | 2.30% | US#2,019/3,111 Sec#146/206 |
| Financial Health | ||
| Debt Ratio | 99.67% | US#1,092/3,111 Sec#106/206 |
| Total Debt | $212M | US#2,194/3,111 Sec#118/206 |
| FCF | $-23M | US#2,392/3,111 Sec#166/206 |
| Cash | $124M | US#2,075/3,111 Sec#131/206 |
| Current Ratio | 2.40x | US#1,042/3,111 Sec#103/206 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,111 Sec—/206 |
| Payout Ratio | 0.00% | US—/3,111 Sec—/206 |
| Performance | ||
| 1Y Return | -22.76% | US#2,642/3,111 Sec#176/206 |
| 1M Return | -49.58% | US#3,099/3,111 Sec#206/206 |
| From 52W High | -64.84% | US#2,979/3,111 Sec#199/206 |
| 1Y MDD | -65.04% | US#2,833/3,111 Sec#180/206 |
| Trading | ||
| Volume | 7,812,920 shares | US#112/3,111 Sec#3/206 |
| Trading Value | $23M | US#1,400/3,111 Sec#94/206 |
| Per Share | ||
| EPS | $-3.95 | US—/3,111 Sec—/206 |
| BPS | $3.94 | US#2,322/3,111 Sec#151/206 |
Company Info
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.